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Objectives: It is important to subdivide Parkinson’s disease (PD) into subtypes, enabling potentially earlier disease
recognition and tailored treatment strategies. We aimed to identify reproducible PD subtypes robust to variations
in the number of patients and features.
Methods: We applied multiple feature-reduction and cluster-analysis methods to cross-sectional and timeless data,
extracted from longitudinal datasets (years 0, 1, 2 & 4; Parkinson’s Progressive Marker Initiative; 885 PD/163
healthy-control visits; 35 datasets with combinations of non-imaging, conventional-imaging, and radiomics
features from DAT-SPECT images). Hybrid machine-learning systems were constructed invoking 16 featurereduction algorithms, 8 clustering algorithms, and 16 classifiers (C-index clustering evaluation used on each
trajectory). We subsequently performed: i) identification of optimal subtypes, ii) multiple independent tests to
assess reproducibility, iii) further confirmation by a statistical approach, iv) test of reproducibility to the size of
the samples.
Results: When using no radiomics features, the clusters were not robust to variations in features, whereas, uti
lizing radiomics information enabled consistent generation of clusters through ensemble analysis of trajectories.
We arrived at 3 distinct subtypes, confirmed using the training and testing process of k-means, as well as
Hotelling’s T2 test. The 3 identified PD subtypes were 1) mild; 2) intermediate; and 3) severe, especially in terms
of dopaminergic deficit (imaging), with some escalating motor and non-motor manifestations.
Conclusion: Appropriate hybrid systems and independent statistical tests enable robust identification of 3 distinct
PD subtypes. This was assisted by utilizing radiomics features from SPECT images (segmented using MRI). The
PD subtypes provided were robust to the number of the subjects, and features.

1. Introduction
Parkinson’s disease (PD) is a chronic, progressive neurodegenerative
disease [1–3]. This disease more affects the population over 65 years of
age [4,5]. PD is defined by widespread neuronal loss [6,7], resulting in a
range of primary motor symptoms. Motor and non-motor symptoms
significantly impact quality of life in PD patients [8–12]. A recent study
shew that cognitive and psychiatric changes are directly linked with PD
progression [13]. Although, there is currently no permanent therapy for

PD, but temporary symptomatic therapies with levodopa [14] and
dopaminergic agonists [15] can improve the quality of life through
alleviation from early symptoms [16,17].
A multicenter study in 10 years following up [18] showed that PD is a
heterogeneous disease so that 9 out of 126 patients needed a wheelchair
unless aided, whereas 13 patients did not show any significant func
tional restriction. Studies of disease progression can be broadly divided
into two categories involving: i) individual symptoms/measures, or ii)
collection of symptoms/measures. In first approach, some studies
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focused on the prediction of outcomes in PD subjects [19–30]. Novel
prognostic biomarkers of PD enable better implementation for
disease-modifying trials [31]. For example, Prashos et al. [32], showed
that motor symptoms are more reliable primary symptoms of disease
progression. In another study by Noyce et al. [33], it was demonstrated
that higher UPDRS III scores cause a lower quality of life in patients with
PD.
Imaging phenotypes, beyond pure usage of clinical measures, have
the potential to add further value to the assessment of PD [21,21,
34–37]. As an example, identification of patients that are symptomatic
without evidence of dopamine deficit (SWEDD) as performed using
dopamine transporter (DAT) SPECT imaging has already made a dif
ference in the recruitment of patients in clinical trials [38,39].
Furthermore, beyond the usage of conventional imaging features, the
field of radiomics has the potential to provide further analysis of im
aging data [21,37,40,41]. In an effort of ours [21], we focused on pre
diction of motor outcome, showing that radiomics features, when added
to clinical features, can significantly improve prediction of outcome. We
later showed that by using hybrid systems (predictive algorithms
accompanied by feature subset selector algorithms), one can obtain
excellent predictions of motor [26] and cognitive [27] outcomes.
Furthermore, our recent ongoing efforts linked with deep learning-based
prediction of outcome showed significant improvements through the
discovery of patterns in images [28].
PD represents heterogeneity in various (not merely individual)
phenotypes for PD subjects [42–45]. As such, definition of PD subtypes
based on collective data could help provide a better understanding of
underlying disease mechanisms, predict disease course, and design
clinical trials [46]. Some studies based on clinical features have
attempted to derive subtypes of PD as a clustering task, as listed in
supplemental Table S1 [31,44,47–50]. Parkinson’s disease (PD) has
been classically introduced as a progressive degenerative motor disease
associated with the degeneration of striatal dopamine neurons [51–55].
Hoehn and Yahr (YH) [56] categorized disease severity into 5 stages.
Since then, stage 0 has been added, and stages 1.5 and 2.5 have been
proposed and are widely used [57]. Patients with H&Y stage 2 have
lower levels of dopamine binding than stage 1 [58], while patients with
H&Y stages 3 and 4 have significantly impaired language function,
working memory and visuospatial function compared to those in stage 2
[59]. In a study by Szewczyk-Krolikowski et al. [60], phenotypic het
erogeneity was documented across age and gender in both motor and
non-motor symptoms. As summarized in Supplemental Table S1, studies
making use of clinical information in the past have categorized patients
into 2 [49], 3 [31,46,61], 4 [44,48,50,62–65], 5 [47,66], 6 [67] or 7
[56,57] sub-clusters. In a recent study [68], previously published
data-driven PD subtype classification systems were re-assessed,
demonstrating limited reproducibility and suggesting a need for the
establishment of standards for validation and use of clustering systems
[68].
However, clinical measurements based on visual examinations in
different clinical centers are prone to errors for defining globally
reproducible PD subtypes. In fact, in general, there have been significant
challenges with the reproducibility of PD subtypes, and a desire for
specific standards for the clustering of PD subjects [68]. There exists an
emerging usage of automated processing invoking machine learning
algorithms for improved task performance without the need for explicit
programming [69]. Approaches based on machine learning aim to
enable improved and automatic classification, prediction, or clustering
by capturing statistically robust patterns present in the analyzed data.
In the present work, we specifically aim to robustly identify subtypes
of PD (an unsupervised clustering task). This is an important key to
better understand underlying disease mechanisms, predict disease
course, and design clinical trials. Furthermore, we incorporate and study
the role of imaging in our analysis, as functional imaging enables spatial
localization of molecular changes as well as accurate and consistent
quantification of their distribution [70,71]. Many machine learning

algorithms are not able to work with many input features, and thus it is
necessary to reduce high feature dimensions into few dimensions to be
used as inputs, as pursued in this work. Overall, in the present work, we
select a range of hybrid algorithms amongst various families of learner
algorithms, and also, various combinations of datasets based on timeless
and cross-sectional approaches are considered, to select robust
sub-clusters of PD which minimally depend on sample size and feature
size.
2. Materials and methods
In what follows we outline our various data selection, image pro
cessing, machine learning and analysis methods. Data and code are
made publicly available (details at the end of this manuscript). In short,
we generated multiple datasets (timeless and cross-sectional), per
formed segmentation and feature extraction, and utilized hybrid ML
systems. We also employed two methods to compare clusters as gener
ated from different datasets. Finally, by dividing datasets on small
groups, we evaluated our finding based on variations into sample size.
Fig. 1 shows different steps of implementation in this study, as elabo
rated next.
2.1. Image processing and feature extraction from regions of interest
(ROIs)
We performed segmentation via two methods, as elaborated next.
2.1.1. Segmentation of dorsal striatum (DS) on DAT SPECT images via T1
weighted MRI
As shown in Supplemental Figure S1 and elaborated in supplemental
section II (part A, i), following few preprocessing steps, we employed the
Free Surfer package to automatically segment T1 weighted-MRI images
and to register SPECT images to MRI data. Fig. 2 shows images related to
the segmentation registration steps. Subsequently, we utilized our
standardized SERA software package [72] (publicly available at:
https://qurit.ca/software/sera/) to extract radiomics features from the
ROIs (left and right caudate and putamen). SERA has been extensively
standardized in reference to the Image Biomarker Standardization
Initiative (ISBI) [73] and studied in multi-center radiomics standardi
zation publications by the IBSI [74] and the Quantitative Imaging
Network (QIN) [75]. There are a total of 487 standardized radiomics
features in SERA, including 79 first-order features (morphology, statis
tical, histogram, and intensity-histogram features), 272 higher-order 2D
features, and 136 3D features. We included all 79 first-order features and
136 3D features [72,74,76].
2.1.2. Direct segmentation of dorsal striatum (DS) on DAT SPECT images
As an alternative approach, we performed direct segmentation based
on the SPECT image itself [77], for greater ease, given the lack of need
for MRI images and computational speed. The multiple steps (x1-x10)
are elaborated in Supplemental Figure S2 (in supplemental section II,
part A.ii). The results of each step are shown in Fig. 3.
2.2. Patient data
As shown in Supplemental Figure S3, 35 datasets extracted from the
PPMI database (www.ppmi-info.org/data) were analyzed. For consis
tency, we only considered patients being off medication (e.g. Levodopa/
dopamine agonist) for >6 h before testing/imaging [78]. Two types of
data-gathering frameworks were used, namely the use of timeless and
cross-sectional datasets. In cross-sectional datasets, we separately
collected information for patients based on each year. Subsequently,
timeless datasets were constructed by appending cross-sectional data
sets within a single set (885/1139 PD subject visits with/without im
aging). This approach aims to gather data with a larger number of
subjects and features. As such, we were able to select datasets with
2
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Fig. 1. The workflow in our study. The 3 types of HMLS are discussed and depicted in subsection C and Supplemental Figure S4.

Fig. 2. Segmentation and fusion process based on MRI segmentation: (top) 3D segmentation of DS; (bottom) (1) T1-weighted MRI image, (2) Segmented MRI, (3)
Fusion of MRI, DAT SPECT, and MRI Segmentation, (4) DAT SPECT, (5) Fusion of DAT SPECT and Segmentation, and (6) Fusion of DAT SPECT and MRI.

different sample sizes and feature sizes (see Supplemental Table S2), to
better study different combinations of features within clustering tasks.
Additionally, we considered 163 healthy-control (HC) subject visits.
Variables included non-imaging clinical features (NCF) and conven
tional imaging features (CIF), as well as radiomics features extracted
from SPECT (RFS) images as segmented via MRI (RFS-M) and SPECT
itself (RFS-S), as elaborated in supplemental section II, part B. Tradi
tionally, quantitative analysis, if performed at all, has been restricted to
assessment of mean regional uptake in different ROIs [36]; by contrast,
in the present work, we move beyond inclusion of conventional features,
to study additional inclusion of radiomics features. To determine the
effect of different categories, we employed combinations of the
above-mentioned categories to study PD clustering:
1.
2.
3.
4.

5. NCF + CIF + RFS-S
6. NCF + RFS-S
7. NCF + RFS-M
2.3. Machine learning methods
We constructed 3 types of hybrid machine learning systems (HMLSs)
(Supplemental Figure S4):
(1) First type employed 3 groups of algorithms: i) 16 Dimensionality
Reduction Algorithms (DRA); ii) 8 Clustering Algorithms (CA); iii) 1
Individual Clustering Evaluation Method (ICEM) for the assessment of
cluster number for each sole trajectory.
(2) Second and (3) Third HMLSs included the above-mentioned al
gorithms in addition to Collective Clustering Evaluation Methods
CCEM1 and CCEM2, respectively, for overall optimization of cluster
number considering various trajectories. CCEM1 focused on correlation
analysis between clusters formed from different trajectories, while
CCEM2 additionally utilized 16 Classifiers (C) to assess classification

NCF only
RFS-M only
NCF + CIF
NCF + CIF + RFS-M
3
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Fig. 3. Segmentation process based on SPECT: (Left) Steps in segmentation (described in supplemental section II, Part A,ii); and (right) showing (1) 3D segmentation
of DS, (2) DAT SPECT, and (3) superposition of DAT SPECT and Segmentation.

accuracy, to arrive at optimal overall cluster number.
These algorithms are elaborated in Supplement Section D and briefly
mentioned next.

in Supplemental section II, part D, iii). Specifically, we selected 16
classifiers: 1) DTC (Decision Tree Classification) [115–117], 2) Lib_SVM
(Library for Support Vector Machines) [118–120], 3) NBC (Naïve Bayes
Classifier) [121,122], 4) KNNC (K Nearest Neighborhood Classifier)
[123,124], 5) ELC (Ensemble Leaner Classifier) [125,126], 6) LDAC
(Linear Discriminant Analysis Classifier) [127,128], 7) New PNNC (New
probabilistic neural network Classifier) [129,130], 8) ECOCMC
(Error-Correcting Output Codes Model Classifier) [131,132], 9 MLP_BP
(Multilayer Perceptron_ Back Propagation) [133,134], 10)RFC (Random
Forest Classifier) [135,136], 11) RNNC (Recurrent Neural Network
Classifier) [137,138], 12), RBFA (Radial Basis Function Algorithm)
[139], 13) LOLIMOT (Local Linear Model Trees Algorithm) [140,141],
and 14, 15, 16) GLMCs (Gaussian Maximum likelihood Classifiers) types
I, II and III (as described in supplemental file) [142–144].
In this work, automated machine learning hyperparameter tuning
was employed to automatically adjust intrinsic parameters such as the
number of neurons, and the number of layers in the classification al
gorithms. We applied this approach to various algorithms such as
LOLIMOT, RBF, RNN, MLP-BP, RFA to automatically tune the parame
ters. Automated tuning, which was implemented with our in-house
code, executes an error minimization search scheme to optimize the
hyperparameters starting with the random initialization. Employing this
approach enables us to pursue a systematic trial-and-error search
scheme for tuning the parameters [26].

2.3.1. Dimensionality reduction algorithms (DRA)
Feature reduction methods are employed to reduce the number of
features in high-dimensional data to a limited number of most relevant
features, thus reducing overfitting. Supervised DRAs requires outcome
for feature subset selection. Unsupervised DRAs need no label for feature
reduction, thus relying on information based on patterns found among
input features [79–81]. In this study, 16 DRAs (only unsupervised) were
employed (as elaborated in Supplemental section II, part D, i): 1) PCA
(Principle Component Analysis) [82], 2) Kernel PCA [83], 3) t-SNE
(t-distributed Stochastic Neighbor Embedding) [84], 4) Factor analysis
(FA) [85], 5) SMA (Sammon Mapping algorithm) [86,87], 6) IsoA
(Isomap Algorithm) [88], 7) LMIsoA (LandMark Isomap Algorithm)
[89], 8) LEA (Laplacian Eigenmaps Algorithm) [90,91], 9) LLEA (locally
linear embedding algorithm) [92], 10) MDSA (multidimensional scaling
Algorithm) [93], 11) DMA (Diffusion map Algorithm) [94,95], 12) SPEA
(Stochastic Proximity Embedding Algorithm) [96], 13) GPLVM
(Gaussian Process Latent Variable Model) [97,98], 14) SNEA (Stochastic
Neighbor Embedding Algorithm) [99], 15), Sym_SNEA (symmetric
Stochastic Neighbor Embedding Algorithm) [100], and 16) AA (Aut
oencoders Algorithms) [101].
2.3.2. Clustering algorithms (CA)
Clustering algorithms, as unsupervised machine learning methods,
employ to identify natural groupings or clusters within multidimen
sional data based on some similarity measure [102–104]. These are all
listed in the Supplement (as elaborated in Supplemental section II, part
D, ii). Our study includes multiple CAs including 1) SOMA (Self-
Organizing Map) [105], 2) APA (Affinity Propagation) [106], 3) HC-WM
(Hierarchical clustering-Ward’s Method) [107], 4) HC-CLA (Hierarchi
cal Clustering -Complete Linkage Algorithms) [108], 5) HC-WLA (Hi
erarchical Clustering -Weighted Linkage Algorithm) [109], 6) KMA
(K-Means Algorithm) [110,111], 7) KMeA (K-Mediods Algorithm) [112,
113], and 8) CwGMMA (Clustering with Gaussian Mixture Model Al
gorithms) [114].

2.3.4. Individual Clustering Evaluation Method (ICEM)
To evaluate clustering solutions, the so-called C-index was utilized
(Supplemental section II, part D, iv). A small value for the C-index in
dicates good clustering [145,146]. We utilized this C-index criterion to
evaluate a range of cluster numbers spanning 2 to 10.
2.3.5. Collective Clustering Evaluation Methods (CCEM 1 and 2)
Because of the variety of optimal cluster solutions in different tra
jectories of the first HMLS (as shown in Supplemental Figure S4), we
considered 2 collective cluster evaluations for final overall cluster
number selection. They utilized 1) Average of Correlation Factors
(AOCF), and 2) Average of Classifier Performances (AOCP; classification
accuracy), constituting final steps in 2nd and 3rd HMLSs, respectively
(Supplemental Figure S4). For a given number of clusters, AOCF
assessed how well results from different clustering methods correlate
with one another, while AOCP assesses accuracies in ultimate

2.3.3. Classifiers (C)
Classifier algorithms are all listed in the Supplement (as elaborated
4
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classification. Overall, given various ML trajectories, AOCF quantifies
and optimizes the overall reproducibility of clusters, while AOCP eval
uates overall reliability (for ultimate classification).

in Supplemental Tables S4 and S5, showing again that the most common
optimal number of clusters is 3. For the rest of our work (below), the
PCA + KMA trajectory was considered for generation and analysis of
disease subtypes, because PCA and KMA were each seen (via ICEM) to
result in the most consistent number of identified clusters when couple
with other methods.

2.4. Analysis procedure
As shown in Fig. 1, we first generated 35 datasets that included
different combinations as listed in section B. All the datasets were
normalized based on the minimum and maximum of each feature. In the
first HMLSs, we employed different hybrid trajectories and determined
the optimal number of clusters for each trajectory (using ICEM). The
optimal numbers of clusters were close to one another (often around 3
clusters), but not always consistent. We then performed ensemble
analysis of trajectories, utilizing CCEM1 as well as CCEM2 (the latter
accompanied by a range of classifiers), to arrive at a collective selection
of optimal cluster number (see Supplemental Figure S4).
For the rest of our analysis, we utilized principal component analysis
(PCA) for feature reduction and k-means algorithm (KMA) for clus
tering, as they each arrived at most consistent number of clusters
(explained later). To assess robustness of our clusters, we pursued 4
approaches: (i) in cross-sectional analysis, for sub-groups obtained via
the hybrid system, we assessed similarity between subtypes (see Sup
plemental Figure S5). To do this we utilized a training and testing pro
cess: following training of KMA using a specific year, the subjects of
another year were processed using the trained model, and the results
were compared with training based on the new set itself (testing). This
enables assessment of the robustness of clusters between datasets. (ii)
We employed High Dimensional Hoteling’s T Squared Test [147] as a
statistical approach (Supplemental section II, part E) for re-confirming
findings. (iii) Furthermore, we made comparisons between clusters
from cross-sectional vs. timeless datasets (see Supplemental Figure S6),
and (iv) finally, by dividing our large timeless datasets into smaller
groups, and then apply the clustering algorithm, to each group, we
evaluated the dependency of our subtype identification on variations in
sample sizes. All algorithms were implemented in the Matlab R 2020 b
platform.

3.2. Second stage analysis including cross-linking different sub-groups
across years
To discover similarity between sub-groups, we performed different
tests as mentioned in section II.D. As shown in Supplemental Figure S5,
after arranging two comparing datasets based on common features, we
re-clustered our datasets with common features. Datasets without
radiomics features were not able to reach consistent results in compar
ison to when we used all features (see Supplemental Tables S6 and S7).
Meanwhile, datasets including radiomics features were able to reach
consistent subtypes (Supplemental Table S8). This comparison shows a
lack of the reproducibility of results based on the usage of clinical fea
tures alone, as also seen elsewhere [148]. Subsequently, we focused on
the additional usage of radiomics features. First, we applied a dataset in
a specific year to KMA. After training the algorithm via a specific year,
we compared subjects of another year as clustered using the trained
model with direct training based on the new year (testing process), to
assess robustness of the identified subtype. Among various datasets,
datasets including RFS-M reached more robust performance (Table 3)
compared to datasets with RFS-S (see Supplemental Tables S9 and S10).
Furthermore, we saw that datasets including RFS-M (e.g. without and
with clinical features) resulted in exactly similar performances. As such,
we concluded that radiomics featured, derived properly using MRI
segmentation, are very important in the clustering of PD.
As an example, cell (2,1) in the top left Table 3 shows how many
patients in G12” (year 1, sub-cluster 2) were associated with G01 (year
0, cluster 1) when we applied test data in year 1 to the network trained
via specific data in year 0. Fig. 4 shows a consistent relationship between
the various sub-clusters as identified in different years (i.e. that they are
effectively similar).
Analysis of both cross-sectional and timeless data arrived at 3
optimal numbers of clusters. As shown in Table 3, the cluster groups
obtained in datasets including RFS-M were more robust compared to
cluster groups obtained by other datasets (see Supplemental Tables S9
and S10), when performing training and testing processes. Moreover,
High Dimensional Hoteling T Squared Test re-confirmed our findings (pvalue<<0.001).

3. Results
3.1. First stage analysis including optimal cluster selection
First, we applied our 35 datasets to the first category of HMLS.
Initially selected numbers of disease subtypes selected via ICEM were
not consistent across different trajectories and datasets. Subsequently,
we applied all datasets to the second and the third HMLSs enabling
ensemble, collective selection of an optimal number of clusters. Tables 1
and 2 show the resulting AOCF and AOCP methods applied to timeless
data respectively. It is seen that for different datasets and methods, the
optimal number of PD sub-clusters is consistently found to be 3. More
over, we also applied these methods to cross-sectional datasets as shown

3.3. Third stage analysis including comparison of timeless sub-groups and
cross-sectional sub-groups
Additional tests aimed to further assess the reproducibility of our
results, and sensitivity to the number of samples. After clustering

Table 1
Clustering scores are based on the AOCF method for timeless data. The maximum score in each dataset (column) is shown in bold. The last column is created by
summing the previous columns.
Cluster number
1.00
2.00
3.00
4.00
5.00
6.00
7.00
8.00
9.00
10.00

NCF + CIF
0.00
0.00
0.26
0.20
0.16
0.12
0.10
0.11
0.08
0.00

NCF + CIF+

NCF + CIF +

RFS-S

RFS-M

0.00
0.00
0.27
0.19
0.16
0.00
0.13
0.00
0.00
0.00

0.00
0.00
0.43
0.32
0.29
0.30
0.20
0.15
0.16
0.00

NCF

NCF + RFS-S

NCF + RFS-M

RFS-M

Overall score

0.00
0.00
0.27
0.20
0.19
0.12
0.13
0.13
0.00
0.00

0.00
0.00
0.36
0.27
0.18
0.20
0.23
0.00
0.08
0.14

0.00
0.00
0.41
0.31
0.31
0.28
0.18
0.00
0.11
0.00

0.00
0.00
0.49
0.37
0.30
0.25
0.21
0.24
0.00
0.00

0.00
0.00
2.50
1.85
1.59
1.26
1.18
0.63
0.42
0.14

5
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Table 2
Clustering scores are based on the AOCP method for timeless data. The maximum score in each dataset (column) is shown in bold. The last column is created by
summing the previous columns.
Cluster number

NCF + CIF

1.00
2.00
3.00
4.00
5.00
6.00
7.00
8.00
9.00
10.00

0.00
0.00
0.92
0.92
0.91
0.00
0.00
0.91
0.91
0.91

NCF + CIF+

NCF + CIF +

RFS-S

RFS-M

0.00
0.00
0.91
0.91
0.91
0.00
0.00
0.00
0.91
0.90

0.00
0.00
0.89
0.88
0.88
0.88
0.88
0.00
0.00
0.88

NCF

NCF + RFS-S

NCF + RFS-M

RFS-M

Overall score

0.00
0.00
0.92
0.91
0.91
0.00
0.91
0.91
0.00
0.00

0.00
0.00
0.88
0.00
0.88
0.88
0.00
0.00
0.00
0.88

0.00
0.00
0.88
0.87
0.87
0.00
0.87
0.00
0.87
0.87

0.00
0.90
0.90
0.00
0.89
0.89
0.00
0.00
0.00
0.00

0.00
0.90
6.28
4.48
6.24
2.64
2.66
1.82
2.68
4.43

radiomics using RFS-M).

Table 3
Association tables for cross-sectional linkage of datasets with RFS-M
Left Table: year-0 dataset used for training, and year-1 dataset used for testing;
Right Table: year-1 dataset used for training, and year-0 dataset used for testing.
GXY shows subtype-Y resulting from a training dataset in year-X, and GZY”
shows the associated patients (in derived subtype-Y from another year-Z) used
for testing.
G11′′
G12′′
G13′′

G01

G02

G03

0.77
0.09
0.14

0.08
0.92
0

0.01
0
0.99

G01′′
G02′′
G03′′

G11

G12

G13

0.96
0.14
0.23

0.03
0.86
0

0.02
0
0.77

3.4. The identified subtypes
We had 3 categories of features, namely motor, non-motor, and
imaging information. We considered 163 HC subject visits for additional
comparison with the identified PD subtypes (images for 40 HC subjects
were analyzed). After normalizing the features based on the minimum
and maximum of each feature, we then assessed PD sub-clusters ac
cording to whether their features had significant differences with HC
subjects (p-value < 0.01; Bonferroni corrected). For plotting in Fig. 5, we
selected features that were significantly correlated with the identified
subtype (Spearman correlation, p-value < 0.01).
Fig. 6 shows a radar plot of the above-mentioned features. What is
different, is that, for improved visibility, we have reversed the orienta
tion of some features (where now higher values mean the worst pro
gression for all features; which we know by correlation with 5 wellunderstood features). And to further simplify, we show the radar after
final normalization based on the maximum value of each feature.
As illustrated, HC subjects (age range: 68 ± 11.4, female: 59, male:
104, Hoehn, and Yahr’s score range: 0.01 ± 0.11) have the lowest scores
compared to PD sub-clusters. PD patients in Cluster I (age range: 69.5 ±
9.8, female: 88, male: 117, Hoehn and Yahr’s score range: 1.71 ± 0.58)
showed slower progression in all domains, including motor and nonmotor symptoms, and imaging, compared to other PD sub-clusters,
while they have higher scores compared to scores in HC subjects. Pa
tients in Cluster II (Age range: 70 ± 9.7, female: 167, male: 125, Hoehn
and Yahr’s score range: 1.70 ± 0.55) have significantly enhanced tremor
among PD sub-clusters, although other symptoms were mostly larger
than those in Cluster I. Cluster III (age range: 71.9 ± 10.9, female: 58,
male: 44, Hoehn and Yahr’s score range: 1.85 ± 0.54) illustrated
significantly enhanced values for various features (except for tremor)
especially the imaging features. The 3 identified subtypes can be
referred to as 1) mild, 2) intermediate, and 3) severe, especially in terms
of dopaminergic deficit (imaging), while also having some escalating
motor and non-motor manifestations.

Left Table: year-1 dataset used for training, and year-2 dataset used for testing; Right
Table: year-2 dataset used for training, and year-1 dataset used for testing
G21′′
G22′′
G23′′

G11

G12

G13

0.69
0
0.31

0
1
0

0
0.24
0.76

G11′′
G12′′
G13′′

G21

G22

G23

1
0
0.18

0
0.43
0

0
0.57
0.82

Left Table: year-2 dataset used for training, and year-4 dataset used for testing; Right
Table: year-4 dataset used for training, and year-2 dataset used for testing
G41
G42′′
G43′′
′′

G21

G22

G23

1
0
0

0.17
0.77
0.06

0
0
1

G21
G22′′
G23′′
′′

G41

G42

G43

0.79
0
0

0.21
1
0.13

0
0
0.87

patients in the timeless dataset, we then split the clustered timeless
dataset into 4 parts based on the original year of each study (i.e. years 0,
1, 2, and 4). As we had also independently clustered cross-sectional data,
this approach allows further investigation of the robustness of our
framework, by comparing the two datasets. We denote patients in a
cluster Y as determined from the timeless dataset, who were originally
from year X, as GTXY. We also denote patients clustered into a cluster Y
directly from the cross-sectional dataset of year X as GCXY. Thus, we
compare subtype in each split category obtained from timeless versus
cross-sectional datasets, as depicted in Table 4.
As an additional investigation, in reverse, we concatenated patients
with similar subtype in cross-sectional datasets of different years into a
clustered timeless set, referred to as GCY for a given sub-type Y. We then
compared this set to GTY, as directly obtained for different subtype Y
from the timeless data. The comparisons are shown in Table 5.
As shown in Tables 4 and 5, results reached from RFS-M datasets are
relatively consistent. These results are in fact more robust compared to
when using NCF + CIF + RFS-S datasets (See Supplemental Tables S11
and S12). At the same time, result of NCF + RFS-S shown in Supple
mental Tables S13 and S14 also depicted good performance, but usage of
this dataset did not enable one to reach as a high cross-linking perfor
mance compared to datasets with RMS-M. As a result, RFS-M performs
well in the clustering task, while other datasets result in less robust
findings. Furthermore, we showed that conventional imaging features
were not effective on their own towards robust clustering (unlike

3.5. Final reproducibility test
This section shows how many samples are needed to reproduce our
findings. As clustering of subjects in datasets containing RFS-M was
similar, we only considered two timeless datasets: i) RFS-M (with 885
subject visits), and ii) NCF (with 1139 subject visits) for reproducibility
analysis. We divided our datasets into various subsets (divisions) from 2
to 30 parts. After applying each data-subset to KMA, we compared the
subtype obtained by split parts, with the original subtype obtained by
the timeless dataset. These correlation coefficients can be introduced as
a standard for the reproducibility test. Figs. 7 and 8 show how much
clustering results changed when sample sizes were reduced. As shown in
Fig. 8, sub-clusters resulting from the NCF dataset were more dependent
6
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Fig. 4. Diagram of the relationship between different sub-cluster groups when utilizing RFS-M for analysis. P-values are calculated by High Dimensional Hotelling’s
T2 Test.

compare subtypes derived from different studied [148]. Though PD is a
heterogeneous disease and longitudinal data is needed to assess PD more
extensively, many studies [31,44,47,48,50,62–64] have used baseline
datasets for clustering PD subjects. Previous efforts did not focus on the
use of radiomics features, and often no imaging information, from which
we conclude that the results may have more strongly dependent on
sample size, and reproducibility remains challenging [148]. Recent
studies and analyses [68,148] have noted prior efforts to have limited
reproducibility, which can also be understood in the context of our
findings. At the same time, we attempt to compare our findings to other
works in Table 6, where we report the average values of features in
sub-clusters. We considered all features reported in each study for our
assessment, though we show then more relevant features in the table.
These comparisons were performed based on the relative progression of
disease between the sub-clusters.

Table 4
Comparison of the split timeless subtype with subtype directly derived from
cross-sectional datasets including RFS-M. GTXY represents the sub-cluster Y
obtained by the timeless dataset as well as split based on year X, and GCXY
represents the sub-cluster Y obtained by the cross-sectional dataset in year X.
GT01

GT02

GT03

GT11

GT12

GT13

GC01
GC02
GC03

0.59
0
0.31

0.41
1
0

0.01
0
0.69

GC11
GC12
GC13

0.73
0
0.37

0.27
1
0

0
0
0.63

GC21
GC22
GC23

GT21
0.96
0
0.16

GT22
0.04
1
0

GT23
0
0
0.84

GC41
GC42
GC43

GT41
1
0
0.4

GT42
0
1
0

GT43
0
0
0.6

Table 5
Comparison of computed subtype obtained by cross-sectional datasets included
RFS-M with subtype obtained by timeless dataset including RFS-M. GTY repre
sents the sub-cluster Y obtained by the timeless dataset, and GCY represents the
formed sub-cluster Y obtained by the cross-sectional datasets.
GC1
GC2
GC3

GT1

GT2

GT3

0.76
0
0.29

0.24
1
0

0
0
0.71

3.7. Independent validation: t-SNE (T-distributed Stochastic Neighbor
Embedding) plot
t-SNE [84] is a machine learning algorithm that performs non-linear
dimensionality reduction to embed high-dimensional data for visuali
zation in a low-dimensional space of two or three dimensions. Specif
ically, it transforms each high-dimensional dataset to 2 or 3 dimensions
in such a way that similar datapoints are modeled by nearby datapoints
and dissimilar datapoints are modeled by distant datapoints with high
probability. We utilized this plot as an independent visualization test of
our efforts to identify PD subtypes. Fig. 9 plots t_SNE results for
cross-sectional years 0, 1, 2 and, 4, as well as timeless data, color-coding
our derived ML-based subtypes and HC group on the plots. The plots
show clear distinctions (particularly along the first dimension) among
the sub-groups.

on sample sizes, while it was already seen before that datasets without
radiomics features strongly depended on features (Supplemental Tables
S6 and S7). The last sub-figure (averaged correlation) especially can be
introduced as a standard to measure reproducibility.
3.6. Comparing our findings to previous studies

4. Discussion

As shown in Fig. 8, the subtypes obtained by the clinical dataset
without radiomics features depend more strongly on sample sizes
compared to those obtained by datasets with radiomics features. In any
case, differences in inclusion criteria from datasets, feature selection,
and methodology between cluster analysis studies make it difficult to

Robust identification of PD subtypes has the potential to guide the
design, and interpretation of clinical trials involving neuroprotective
and symptomatic therapy [149]. To this end, we explored the applica
tion of hybrid machine learning systems (HMLSs) to two datasets,
7
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Fig. 5. Bar plot of three kinds of features, motor (dark blue text), imaging (purple text) and non-motor (green text) for our 3 identified PD sub-clusters and
HC groups.

Fig. 6. Radar plot of three kinds of features, motor (dark blue text), imaging (purple text) and non-motor (green text) for our 3 identified PD sub-clusters and
HC groups.

8
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Fig. 7. Reproducibility test based on timeless RFS-M dataset. X axis represents the number of parts the dataset was divided into, and Y axis represents the correlation
between specific subtype resulting from each data subset (division) and the original subtype from the entire dataset. The first three plots show the correlations for the
three clusters and the fourth one shows the means and standard deviations of the correlations in the three clusters.

Fig. 8. Reproducibility test based on timeless NCF dataset. X axis represents the number of parts the dataset was divided into, and Y axis represents the correlation
between specific subtype resulting from each data subset (division) and the original subtype from the entire dataset. The first three plots show the correlations for the
three clusters and the fourth one shows the means and standard deviations of the correlations in the three clusters.

namely cross-sectional and timeless, both of which resulted in robust PD
subtypes. Overall, we arrived at 3 distinct subtypes among PD patients
using cluster analysis with a comprehensive range of variables including
both non-imaging information and radiomics features.

In our work, using solely clustering cost (sum of subject distances in
each cluster compared to their cluster centers) did not enable one to
select a unique optimal cluster number (see Supplemental Table S3).
Thus, we employed additional costs such as AOCF (reproducibility test)
9
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Table 6
Comparison of our findings with other related works. Subtypes (e.g. I) in the different studies do not necessarily correspond to one another but are listed in relative
order of severity.
Present work

Subclusters
MS (U-III)
NMS (STSec-2)
RMF (L-PuEn)

I. Mild

II. Moderate

III. Severe

22.82 ± 10.77
31.75 ± 10.05

24.22 ± 10.73
32.6 ± 9.64

25.41 ± 11.96
33.72 ± 10.9

(2.56 ± 0.45) e11

(1.75 ± 0.4) e11

(0.70 ± 0.37) e11

Fereshtenejad et al.
[46]

Subclusters
MS (U-III)
NMS (U–I)

I. Mainly motor/slow progression

II. Intermediate

III. Diffuse/malignant subtype

17.7 ± 7.5
4.4 ± 3.1

24.1 ± 9
6±4

27.3 ± 9.4
10.8 ± 4.9

Lui et al. [65]

Subclusters
MS (UIII/
DD)
NMS
(MMSE)

III. Tremor
dominant
4.82 ± 2.64

IV. Young onset

I. Non-tremor dominant

II. Worse disease progression

5.59 ± 3.39

16.84 ± 4.56

36.57 ± 7.89

27.02 ± 2.66

27.64 ± 2.07

26.79 ± 3.95

26.43 ± 2.76

Reijnders et al.
[63]

Subclusters
MS (T)
NMS
(MMSE)

II. Young onset

IV. Tremor-dominant

0.6 ± 0.6
28.2 ± 1.8

1.1 ± 0.8
27.7 ± 2.3

I. Worse disease
progression
0.9 ± 0.6
24 ± 4.7

Lewis et al. [44]

Subclusters
MS (U-III)
NMS (VF)

I. Younger disease onset

II. Tremor
dominant
25 ± 12
40 ± 12

Gasparoli et al.
[49]

Subclusters
MS (UMS)
NMS (D)

I. Slow progression

II. Rapid progression

11.9 ± 3.9
9.5 ± 0

25.1 ± 5.1
12.5 ± 0

Rooben et al. [62]

Subclusters

I. Mildly affected in
all domains

II. Severe motor
complications

MS (T)
NMS (CI)

3.6 ± 1.9
14.7 ± 5.5

3.1 ± 1.8
15.8 ± 4.8

Subclusters
MS (UME/
DD)
NMS
(MMSE)

Post et al. [31]

21 ± 10
46 ± 13

IV. Non-tremor
dominant
28 ± 13
33 ± 12

III. Non-tremordominant
0.7 ± 0.8
17.4 ± 7.7

III. Rapid disease progression
30 ± 11
44 ± 9

III. Affected mainly on
nondopaminergic domains without
prominent motor complications
4.1 ± 2.2
19.7 ± 5.4

IV. Severely affected on all domains

I. Younger onset

II. Intermediate older onset

III. Oldest onset

0.7

0.8

1.7

28.7

27.1

26.9

1.5 ± 3.1
25.7 ± 5.1

MS: Motor symptoms, MCS: Motor Composition Score, RMF: Radiomics features, U-III: UPDRS III, L-Pu_En: Left Putamen Energy, ST-Sec-2: STAIA-section 2, U–I:
UPDRS I, UIII/DD: UPDRS III/disease duration, MMSE: Mini-Mental State Examination, T: Tremor, VF: Verbal Fluency, UMS: UPDRS motor score, D: Depression, CI:
Cognitive impairment, UME/DD: UPDRS-Motor examination per disease duration.

Fig. 9. t_SNE plot for NCF + CIF + RFS-M dataset. Clusters I, II and, III were identified in our ML-based effort, independently validated by this plot. The right figure
also includes healthy-control (HC) patients for comparison.
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and AOCP (reliability test) for selecting optimal cluster number in each
dataset, overall arriving at 3 distinct PD subtypes. Moreover, we showed
that the use of multiple HMLSs worked more effectively than the sole
usage of clustering algorithms and classifiers (see section III, part A). As
a result, the PCA + KMA trajectory was shown as an optimal trajectory
among the various trajectories for the generation and analysis of disease
subtypes. PCA and KMA were each seen (via ICEM) to result in the most
consistent number of identified clusters (as shown in 3 last tables within
Supplemental Table S3, resulted from the datasets with RFS-M). To
further evaluate our identified subtypes, we performed similarity iden
tification tests across cross-sectional datasets in each category. To
identify the similarity between subtypes, first, we utilized the training
and testing process of KMA. After training the algorithm by a specific
year, we associated subjects of another year with the resulting clusters
(testing process). After comparing the associated subjects with the
original test sub-groups, we were able to identify similar clusters.
As shown in Supplemental Table S2, the datasets were generated
according to the maximum sample size and maximum feature size.
Before cross-linking cross-sectional phenotypes, we selected common
features between 2 datasets comparing. After re-clustering crosssectional datasets by common features, we were only enabled to reach
similar clusters using datasets with radiomics features compared to
when using all features (see Supplemental Table S8). According to
Supplemental Table S6 and Supplemental Table S7, it seemed that the
subtypes were sensitive to the reduction in clinical features when using
no radiomics features.
In recent studies [68,148], it was recommended that researchers
should employ methods resulting in reproducible subtypes. As seen in
Supplemental Table S1, different studies employing a given dataset with
limited features for clustering PD subjects resulted in different optimal
numbers. The selections of specific features in clustering can result in a
different number of optimal sub-clusters (Supplemental Table S3). One
of the most important rules in clustering approaches is the dependency
check of sub-groups on the size of features [148]. As seen in the results
section, datasets without radiomics features are strongly dependent on
the size of clinical features. Unlike this work, to the best of our knowl
edge, previously published works did not employ radiomics features or
even imaging information for PD subtype identification (clustering) [31,
44,46–50,61–64].
As shown in Table 3, associations in combinations with RFS-M were
more robust compared to combinations with RFS-S (see Supplemental
Table S9 and Supplemental Table S10). Thus, we were able to verify 3
distinct subtypes, across the cross-sectional datasets and timeless data
set. Moreover, Hotelling’s T2 test re-confirmed our findings (see Fig. 4).
As shown in Fig. 9, the distributions of cross-sectional datasets with RFSM were similar to the timeless dataset. This plot can also be introduced
as a powerful independency test among the sub-groups. These plots
properly showed clear differences (especially on the first dimension)
among the sub-groups.
In a recent study of ours [36], conventional mean uptake analysis
showed no correlations with clinical measures in PD subjects in either
the caudate and putamen. By contrast, significant correlations were
observed for radiomics features, against motor and cognitive measures
as well as disease duration. As a result, it can be concluded that RFS-M is
potentially very important for the clustering of PD subjects. Moreover,
radiomics features of DAT SPECT images, going beyond conventional
imaging measures, were seen to provide significant improvements in
prediction [21] and diagnosis tasks [37]. Overall, radiomics features
have shown considerable potential as biomarkers of PD progression [34,
35].
Subsequently, we assessed the dependency of our results on sample
size. As shown in Tables 4 and 5, datasets with RMS-M overall resulted in
better performance than other datasets shown in Supplemental Table
S11-S12; the final reproducibility test confirmed our findings (see
Fig. 7). Although the results of NCF + RFS-S shown in Supplemental
Table S13- S14 also indicated good performance, usage of this dataset

does not enable reaching appropriate cross-linking performance
compared to datasets with RMS-M (see Supplemental Table S10).
Overall, we believe, this is an important towards development of robust
models, not considered in prior works [31,44,46–50,61,63,64].
Reproducing results of previous studies is difficult because the
datasets used are different. Furthermore, clustering results did not
employ imaging features and may depend on sample size or feature size
as discussed already. In recent studies [68,148], analysis of previously
published data-driven PD subtype classification systems suggested a lack
of reproducibility and need for the establishment of standards for vali
dation and the use of clustering systems. Clinical measurements based
on visual examination in different clinical centers have several sources
of error and can be a major challenge. A systematic analysis of images
may provide help to this end. Thus, RFS-M, e.g. generated through our
SERA radiomics software [72] standardized using guidelines from the
IBSI (Image Biomarker Standardization Initiative) [73], can be a valu
able step towards reproducible research. As shown, cluster results of
combinations with RFS-M are more robust to variation in the size of the
samples, and feature compared to other results, and the final repro
ducibility test confirmed our findings (see Fig. 7). Since motor symptoms
[16,51–55] as well as non-motor symptoms [51,54,55,150–155] in PD
subjects strongly correlate with neuronal dysfunction in the brain,
radiomics features have the potential to capture and correlate with at
tributes of both symptomatic groups [71]. As seen, all combinations
including RFS-M, even the use of RFS-M alone, enabled us to reach
similar clusters. As a result, it can be seen that radiomic features
uniquely determine PD subtypes identified in this work.
Fig. 6 showed the relative progression of disease between the subclusters. The subjects in the HC group depicted dramatically lower
scores among the PD subtype in all domains, including motor symptoms,
non-motor symptoms, and imaging information. Sub-cluster I had lower
scores compared to other PD sub-clusters. Thereby, the patients in this
sub-cluster appear in a less progressed stage of disease in all domains
than those in other PD subtypes. The patients in sub-cluster II indicated
worse tremor across all groups, although, other symptoms (except
Hoehn and Yahr’s score) were bigger than those in sub-cluster I, lower
than those in sub-cluster III. Patients in sub-cluster III had the worst
symptoms (except tremor) among PD sub-clusters. The patients in this
sub-cluster had the worst neuronal loss in the substantia nigra with the
loss of dopaminergic terminals in the basal ganglia [156,157], whilst,
motor and non-motor symptoms had lower progression than those in
other sub-clusters. In short, our 3 identified subtypes are 1) mild, 2)
intermediate and 3) severe, especially in terms of dopaminergic deficit
(imaging), but also with motor and non-motor manifestations.
Differences in inclusion criteria from datasets, in feature selection,
and in methodology between cluster analysis studies have made it
difficult to compare the subtypes [148]. We note that a recent study
indicated that tremor is not an independent indicator of a benign disease
course, thus we did not emphasize it for defining the name of
sub-clusters [158]. As shown in Supplemental Table S1, Hoehn, and
Yahr (YH) [56] introduced disease severity into 5 stages. Since then,
stage 0 has been added, and stages 1.5 and 2.5 have been proposed and
are widely used [56,57]. Overall, patients with higher H&Y scores have
been reported to have a poorer quality of life [159]. Based on Table 6,
we provide a relative comparison of sub-clusters obtained in different
efforts. These comparisons were performed based on the relative pro
gression of disease between the sub-clusters. Fereshtenejad et al. [46]
found three sub-clusters. The relative progression of disease among their
sub-clusters I, II and, III appears somewhat related to ours in sub-clusters
I, II and, III. Post et al. [31] also defined 3 sub-clusters. By comparison,
Lui et al. [65], Reijnders et al. [63], Lewis et al. [44] and, Rooben et al.
[62] identified 4 sub-clusters, and we have attempted to roughly map
their clusters to relevant columns, indicating the relative progression of
the disease. Finally, Gasparoli et al. [49] found only two sub-clusters,
which we also summarize. At the same time, as emphasized above,
these various sub-clusters are likely not similar (e.g. as imaging was not
11
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utilized, and different methods and patient data were utilized).
The limited size of a dataset is a limiting factor in PD subtype iden
tification; as such, to maximize our numbers as well as to maximize our
features, we had to select different sets. Another approach we used to
tackle this limitation was the usage of timeless datasets. In our work, we
used dimensionality reduction algorithms to reduce the size of features
to avoid overfitting, although it was possible to utilize feature selection
algorithms that we hope to explore in future work. Furthermore, our
study is for a particular cohort of patients, and our findings should be
externally validated on an independent database.
At the same time, there are many advantages to this study. Impor
tantly, we utilized a very comprehensive database including a broad
spectrum of non-imaging and imaging features. Furthermore, our study
focused on the added value of imaging, including the generation of
radiomics features, in a standardized manner, based on guidelines from
the IBSI, aiming towards the identification of a robust PD subtype.
Furthermore, there is evidence that a cross-sectional only analysis
cannot accurately reveal the progression of the disease [160,161], and
the strength of our study is additional the usage of the timeless dataset
formed from longitudinal data, enabling a more balanced definition of
subtype. In the future, we aim to investigate optimal feature selection
and machine learning methods for both tasks of i) clustering of PD
subjects and ii) predicting PD outcome (e.g. disease subtype in year 4).
Moreover, we aim to identify distinct disease progression pathways in
Parkinson’s disease (PD), utilizing clustering of time-series data (longi
tudinal clustering), and relating disease progression pathways to PD
subtypes.

Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.compbiomed.2020.104142.
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